Spleen deficiency with dampness pattern diarrhea is a diagnosis rooted in traditional Chinese medicine that overlaps substantially with chronic functional diarrhea and diarrhea-predominant irritable bowel syndrome as understood in Western medicine. In traditional medical theory, the condition arises when the digestive system loses its capacity to transform and transport fluids, producing loose stools, fatigue, poor appetite, and abdominal discomfort. Clinically, Weiling Decoction has been used for such patients for years, but the pharmacological basis of its effects has remained poorly characterized. The new study set out to close that gap by combining modern analytical chemistry with high-throughput genomic sequencing.

The research team, led by corresponding author Ying Cai, first established a mouse model of the syndrome by exposing Kunming mice to high-humidity environments and administering oral lard, a combination designed to replicate the cold, damp conditions and dietary factors associated with the disorder. The team then turned to an ultra-high-performance liquid chromatography tandem mass spectrometry workflow, known as UHPLC-MS/MS, to chemically fingerprint Weiling Decoction. This analysis identified twenty primary bioactive compounds in the formula, including vicenin-1, inosine, and chlorogenic acid, each of which has documented anti-inflammatory or metabolic activity in previous literature.

With the chemical profile in hand, the researchers evaluated how the formula performed therapeutically. Histological examinations of small intestinal tissue revealed that treated mice showed a marked restoration of villus length, the finger-like projections that absorb nutrients in the gut and are often damaged or shortened in diarrheal disease. Treated animals also exhibited a higher density of goblet cells per unit area, specialized cells that produce the protective mucus layer lining the intestinal wall. These structural changes suggest that the decoction does more than suppress symptoms; it appears to actively support the repair and maintenance of the intestinal mucosal barrier.

Biochemical assays reinforced the picture of a remedy that rebalances disrupted signaling networks. Serum levels of cyclic adenosine monophosphate, or cAMP, a molecule central to regulating fluid secretion in the gut, rose in treated mice alongside increases in D-xylose, a marker of intestinal absorptive capacity, and gastrin, a hormone that stimulates digestive function. Meanwhile, levels of cyclic guanosine monophosphate, or cGMP, and vasoactive intestinal peptide, or VIP, both of which promote intestinal secretion and can exacerbate diarrhea when overproduced, were reduced. Together these shifts indicate that the formula helps recalibrate what the researchers describe as the gastrointestinal-water-energy regulatory network, a coordinated system of hormonal and second-messenger signals that governs how the gut manages fluids and energy.

The heart of the study lies in its microbiome analysis. Using 16S rRNA gene sequencing, the researchers surveyed the bacterial populations in the small intestinal contents of the mice and found that treatment with Weiling Decoction significantly increased the relative abundance of three bacterial genera: Limosilactobacillus, Dwaynesavagella, and Paramuribaculum. Limosilactobacillus, a genus that includes well-known probiotic species, has been repeatedly linked to gut barrier protection and anti-inflammatory effects. Shifts in these bacterial populations suggest the decoction works in part by nurturing a microbial community better equipped to maintain intestinal homeostasis.

To probe what these microbial changes might mean functionally, the team applied PICRUSt2, a computational tool that predicts the metabolic capabilities of microbial communities based on their genetic profiles. The analysis pointed to secondary bile acid biosynthesis as a potentially critical mechanistic pathway. Secondary bile acids are produced when gut bacteria chemically modify the bile acids released by the liver, and a growing body of research links these microbial metabolites to intestinal immune regulation, epithelial barrier integrity, and metabolic signaling. The finding is consistent with recent work showing that gut symbionts can alleviate metabolic and inflammatory disease through secondary bile acid pathways, and it places Weiling Decoction’s effects within a rapidly expanding framework of microbiome-mediated pharmacology.

The study’s authors are careful to frame their findings as correlative rather than definitively causal, noting that the results suggest a microbiota-associated pharmacological mechanism rather than proving one outright. Direct evidence that transplanting the altered microbiota reproduces the therapeutic effect, for instance through fecal microbiota transplantation experiments, remains a logical next step. Nonetheless, the convergence of histological repair, biochemical normalization, and microbial restructuring in the same animals provides a coherent and testable model for how the formula may exert its clinical effects.

From a broader perspective, the research speaks to a growing scientific interest in what traditional Chinese medicine practitioners call syndrome-matched treatment, the idea that therapies should be tailored not just to a disease label but to the specific pattern of dysfunction an individual patient exhibits. By characterizing both the chemical constituents of Weiling Decoction and the molecular and microbial consequences of its administration, the study provides what the authors describe as a biotechnological basis for such syndrome-targeted approaches to gastrointestinal disorders. The data underlying the microbiome analysis have been deposited in the NCBI Sequence Read Archive under accession number PRJNA1346698, allowing other researchers to scrutinize and extend the findings.

Chronic diarrhea remains a substantial global health burden, and conventional treatments often manage symptoms without addressing the underlying disruptions in gut ecology and signaling that drive recurrence. If the mechanisms identified in this mouse model hold up in further studies, including controlled human trials, Weiling Decoction could offer a template for developing microbiome-directed therapies that restore gastrointestinal function by working with, rather than against, the body’s resident microbial communities. For now, the study stands as a compelling example of how modern analytical tools, from mass spectrometry to gene sequencing, can illuminate the biological logic hidden within traditional remedies and potentially translate ancient clinical wisdom into the pharmacological language of the twenty-first century.

Subject of Research: Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea through modulation of intestinal microbiota

Article Title: Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota

Article References: Yu, D., Long, Q., Tian, Q., Zhang, X., Li, D., Tan, Z., & Cai, Y. (2026). Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota. 3 Biotech, 16(10), Article 421. https://doi.org/10.1007/s13205-026-05052-y

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05052-y

Keywords: Weiling Decoction, traditional Chinese medicine, intestinal microbiota, diarrhea, 16S rRNA sequencing, UHPLC-MS/MS, spleen deficiency with dampness pattern, secondary bile acids, gut barrier, PICRUSt2, Limosilactobacillus, gastrointestinal health